In multiple myeloma (MM), we have shown that HDAC6 knockdown or treatment with the selective small molecule HDAC6 inhibitors tubacin [2], ricolinostat [3], and WT161 [4], synergistically enhances bortezomib-induced cytotoxicity. Here, HDAC6 is linked to plasma cell myeloma.